Inovio Pharmaceuticals (NYSEMKT:INO) enters into an at-the-market deal with Stifel, Nicholas & Co. for the sale of up to $100M of its common stock. Stifel will earn a 3% commission for its efforts.
READ FULL ARTICLE HERE
Inovio Pharmaceuticals (NYSEMKT:INO) enters into an at-the-market deal with Stifel, Nicholas & Co. for the sale of up to $100M of its common stock. Stifel will earn a 3% commission for its efforts.
READ FULL ARTICLE HERE